T-DXd was first FDA-approved for this indication in 2019, and it has since also been approved for HER2-low metastatic breast cancer, HER2-positive advanced gastric cancer, and HER2-mutant metastatic non-small-cell lung cancer. Here, ERBB2 is linked to non-small cell lung carcinoma.